Content about Pharmacy

April 10, 2014

Lupin announced that it received final approval from the Food and Drug Administration for pioglitazone tablets USP in 15-mg, 30-mg and 45-mg strengths.

MUMBAI and BALTIMORE — Lupin announced that it received final approval from the Food and Drug Administration for pioglitazone tablets USP in 15-mg, 30-mg and 45-mg strengths. The product is the generic version of Actos tablets from Takeda Pharmaceuticals.

The drug is used an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes. Actos tablets had annual sales in the United States of approximately $236 million as of December 2013, according to IMS MAT data. 

 

April 10, 2014

In the wake of acquiring Houston-based RediClinic, Rite Aid on Thursday reported revenues of $6.6 billion for the fourth quarter ended March 1, resulting from a 2.2% lift primarily attributed to an increase in pharmacy same-store sales.

CAMP HILL, Pa. — In the wake of acquiring Houston-based RediClinic, Rite Aid on Thursday reported revenues of $6.6 billion for the fourth quarter ended March 1, resulting from a 2.2% lift primarily attributed to an increase in pharmacy same-store sales. For the full year, Rite Aid reported $25.5 billion in revenues, up 0.5%.

April 9, 2014

Emphasizing implementation challenges that could impact patient access to pharmacy services, a coalition is urging Secretary of Health and Human Services Secretary Kathleen Sebelius to allow a one-year transition period for states to fully implement the Medicaid average manufacturer’s price-based federal upper limits for prescription medications.

ARLINGTON, Va. — Emphasizing implementation challenges that could impact patient access to pharmacy services, a coalition is urging Secretary of Health and Human Services Secretary Kathleen Sebelius to allow a one-year transition period for states to fully implement the Medicaid average manufacturer’s price-based federal upper limits for prescription medications.

April 9, 2014

OutcomesMTM on Tuesday recognized its top chain and independent pharmacies for 2013.

DES MOINES, Iowa — OutcomesMTM on Tuesday recognized its top chain and independent pharmacies for 2013. New winners took home the Top Chain categories, with Kroger being named Top Large Pharmacy Chain and Discount Drug Mart designated as Top Regional Pharmacy Chain. In addition, 42 chain and independent pharmacies were awarded Top MTM Center for their states.

April 9, 2014

As the cost for specialty medications continues to rise, implementing an effective "channel transition" approach — the process of moving prescriptions from the medical benefit to the pharmacy benefit — can produce significant savings for healthcare payers by improving management of these complex and costly drugs, according to a new report commissioned by CVS Caremark.

WOONSOCKET, R.I. — As the cost for specialty medications continues to rise, implementing an effective "channel transition" approach — the process of moving prescriptions from the medical benefit to the pharmacy benefit — can produce significant savings for healthcare payers by improving management of these complex and costly drugs, according to a new report commissioned by CVS Caremark.

April 9, 2014

According to new survey data recently released by the National Consumers League, one-third of adult Americans still believe that vaccines may be linked to autism in children.

WASHINGTON — According to new survey data recently released by the National Consumers League, one-third of adult Americans still believe that vaccines may be linked to autism in children. According to the survey, 33% of parents of children under the age of 18 and 29% of all adults continue to believe “vaccinations can cause autism.” Scientific studies have clarified that use of vaccines is not linked to autism in children, the NCL noted. 

April 8, 2014

Diplomat on Monday announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla (apremilast), a new medication for the treatment of psoriatic arthritis.

FLINT, Mich. — Diplomat on Monday announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). 

Otezla was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. 

April 8, 2014

Healthcare Distribution Management Association president and CEO John Gray on Monday testified before the House Energy and Commerce Subcommittee on Health at a hearing on “Improving Predictability and Transparency in DEA and FDA Regulation.”

ARLINGTON, Va. — Healthcare Distribution Management Association president and CEO John Gray on Monday testified before the House Energy and Commerce Subcommittee on Health at a hearing on “Improving Predictability and Transparency in DEA and FDA Regulation.” HDMA is in support of the Ensuring Patient Access and Effective Drug Enforcement Act of 2014, H.R. 4069, sponsored by Reps. Marino, R-Pa., and Blackburn, R-Tenn. 

April 8, 2014

Ohio Gov. John Kasich got his first look on Tuesday at what’s being called a next-generation pharmaceutical distribution center — under construction in central Ohio.

COLUMBUS, Ohio — Ohio Gov. John Kasich got his first look on Tuesday at what’s being called a next-generation pharmaceutical distribution center — under construction in central Ohio.

AmerisourceBergen’s new national distribution center will process approximately 96 million units of medication daily. The facility is expected to employ 100 associates when it opens in the fall of 2014. The company already employs nearly 500 people in the Columbus area.  

April 8, 2014

Rite Aid on Tuesday announced it has been awarded Specialty Pharmacy accreditation from URAC, a Washington, D.C.-based healthcare accreditation organization that establishes quality standards for the healthcare industry.

CAMP HILL, Pa. — Rite Aid on Tuesday announced it has been awarded Specialty Pharmacy accreditation from URAC, a Washington, D.C.-based healthcare accreditation organization that establishes quality standards for the healthcare industry. 

April 8, 2014

Sunovion Pharmaceuticals on Monday announced that Aptiom (eslicarbazepine acetate), a once-daily antiepileptic drug, is now available across the United States.

MARLBOROUGH, Mass. — Sunovion Pharmaceuticals on Monday announced that Aptiom (eslicarbazepine acetate), a once-daily antiepileptic drug, is now available across the United States.

The drug, which received approval from the Food and Drug Administration on Nov. 8, 2013, is a prescription medicine used with other medicines to treat partial-onset seizures. The drug is available in four table strengths: 200 mg, 400 mg, 600 mg and 800 mg; it can be taken whole or crushed, with food or without.

April 8, 2014

Teva Pharmaceutical Industries announced that it has received approval from the Food and Drug Administration for its generic form of Lovaza (omega-3-acid ethyl esters capsules, USP) in the United States.

JERUSALEM — Teva Pharmaceutical Industries announced that it has received approval from the Food and Drug Administration for its generic form of Lovaza (omega-3-acid ethyl esters capsules, USP) in the United States.

Lovaza is used as an adjunct to diet to reduce triglycerdide levels in adult patients, according to the FDA. Teva believes it is the first to file and plans to begin shipping immediately.

Lovaza capsules, marketed by GlaxoSmithKline, had annual sales of $1.1 billion in the United States as of December 2013, according to IMS data.

 

April 8, 2014

Upsher-Smith has announced the release of the first in a series of educational e-books authored by Hamacher Resource Group and created for independent community pharmacists.

WAUKESHA, Wis. — Upsher-Smith has announced the release of the first in a series of educational e-books authored by Hamacher Resource Group and created for independent community pharmacists.

The first e-book in the series is “Community Pharmacy: Foundation for the Future,” and was developed to assist independent pharmacists/owners with assessing the state of their business and preparing strategies for continued growth.

April 7, 2014

The American Pharmacists Association Foundation has announced the elected officers for its board of directors for the 2014-2015 term: Ed Hamilton as president, Mark Cziraky as VP and Bruce Laughrey as treasurer.

WASHINGTON —The American Pharmacists Association Foundation has announced the elected officers for its board of directors for the 2014-2015 term:  Ed Hamilton as president, Mark Cziraky as VP and Bruce Laughrey as treasurer.

The officers were officially installed during the APhA Foundation board meeting in conjunction with the APhA2014 Annual Meeting & Exposition in Orlando.

April 7, 2014

Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate), which is used to treat deep venous thrombosis and pulmonary embolism.

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate). The drug is indicated for the treatment of deep venous thrombosis and pulmonary embolism in patients who have received a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated, the company said.

April 7, 2014

In an effort to more accurately reflect the makeup of Kinney Drugs’ diverse range of pharmacy-related health care services, the company has decided to change its name to KPH Healthcare Services.

GOUVERNEUR, N.Y. — In an effort to more accurately reflect the makeup of Kinney Drugs’ diverse range of pharmacy-related health care services, the company has decided to change its name to KPH Healthcare Services.

“We believe that the name change will afford each of our divisions the best opportunity to grow business within existing markets, as well as position them for expansion into new markets,” the company said in a statement sent to Drug Store News.

April 7, 2014

Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.

DUBLIN — Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. The transaction was unanimously approved by the boards of directors of both companies. Subject to customary closing conditions, the transaction currently is expected to be completed in the third calendar-quarter of 2014.

April 7, 2014

McKesson on Monday announced that the results of the initial acceptance period of the voluntary public takeover offer for the remaining shares of Celesio AG have been published.

SAN FRANCISCO — McKesson on Monday announced that the results of the initial acceptance period of the voluntary public takeover offer for the remaining shares of Celesio AG have been published. 

McKesson now owns 75.7% of Celesio shares on a fully diluted basis.

Shareholders who did not tender their Celesio shares into the takeover offer during the initial acceptance period may tender their shares within the additional two-week acceptance period. The additional two-week acceptance period will begin on April 8 and will expire on April 22.

April 7, 2014

OncologyRx Care Advantage, McKesson Specialty Health’s oral oncology products specialty pharmacy, on Monday announced that they have assisted under-insured patients in obtaining $40 million in financial assistance by helping them access financial assistance programs.

THE WOODLANDS, Texas — OncologyRx Care Advantage, McKesson Specialty Health’s oral oncology products specialty pharmacy, on Monday announced that they have assisted under-insured patients in obtaining $40 million in financial assistance by helping them access financial assistance programs.

“Without this financial support, most of these patients simply would not be able to obtain the medication they need to continue treatment," said Larry Whisenant, director of Specialty Pharmacy Operations, OncologyRx Care Advantage. 

April 7, 2014

Registration is now open for McKesson ideaShare 2014, McKesson’s annual education and networking event for independent pharmacy owners from across the nation.

SAN FRANCISCO — Registration is now open for McKesson ideaShare 2014, McKesson’s annual education and networking event for independent pharmacy owners from across the nation. This year’s conference will take place July 20–24, 2014, at the Gaylord Palms Resort in Orlando, Fla. For more than three decades, McKesson’s annual trade show and conference has provided opportunities for attendees to share best practices and learn about the latest trends, technology and clinical solutions to help them better serve their patients and achieve better pharmacy health.

April 7, 2014

Sun Pharma on Sunday announced it will acquire 100% of Ranbaxy in an all-stock transaction valued at $4 billion.

MUMBAI, India — Sun Pharma on Sunday announced it will acquire 100% of Ranbaxy in an all-stock transaction valued at $4 billion. 

The combination of Sun Pharma and Ranbaxy creates the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India, Sun Pharma stated. The combined entity will have operations in 65 countries, 47 manufacturing facilities across five continents, and a significant platform of specialty and generic products marketed globally, including 629 abbreviated new drug applications. 

April 4, 2014

IMS Health Holdings on Thursday announced the pricing of its initial public offering of 65 million shares of its common stock at a price to the public of $20 per share, including 52 million shares to be sold by IMS Health and 13 million shares to be sold by selling shareholders.

DANBURY, Conn. — IMS Health Holdings on Thursday announced the pricing of its initial public offering of 65 million shares of its common stock at a price to the public of $20 per share, including 52 million shares to be sold by IMS Health and 13 million shares to be sold by selling shareholders. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 9.75 million shares of common stock at the public offering price, less underwriting discounts and commissions.  

April 4, 2014

The National Association of Boards of Pharmacy recommended that pharmacies no longer dispense combination drugs containing more than 325 mg of acetaminophen per dosage unit in light of recent regulatory action.

MOUNT PROSPECT, Ill. — The National Association of Boards of Pharmacy on Wednesday recommended that pharmacies no longer dispense combination drugs containing more than 325 mg of acetaminophen per dosage unit in light of recent regulatory action.  

NABP also advises that pharmacists consult with prescribers to discuss alternative products with lower acetaminophen doses.

April 4, 2014

Medication nonadherence is common, but it may be reduced by lower drug costs and co-payments, as well as increased follow-up care, according to a study published earlier this week in the Annals of Internal Medicine.

PHILADELPHIA — Medication nonadherence is common, but it may be reduced by lower drug costs and co-payments, as well as increased follow-up care, according to a study published earlier this week in the Annals of Internal Medicine

Primary nonadherence was defined as not filling an initial prescription within nine months. 

April 4, 2014

Hospital patients who participated in Walgreens' WellTransitions program were 46% less likely to experience an unplanned hospital readmission within 30 days of discharge, according to new company research released Friday.

DEERFIELD, Ill. — Hospital patients who participated in Walgreens' WellTransitions program were 46% less likely to experience an unplanned hospital readmission within 30 days of discharge, according to new company research released Friday.